Kenox Pharmaceuticals Achieves Clinical Manufacturing Readiness for Nasal and Inhaled Drug Products

Kenox Pharmaceuticals Inc. has announced that it is now clinically ready to manufacture nasal and inhaled drug products, marking a significant milestone in its development capabilities. The company has also expanded its GMP analytical testing services, including in-vitro bioequivalence (IVBE) testing, to support innovators developing orally inhaled and nasal drug products (OINDPs). These integrated capabilities enable Kenox to provide end-to-end support from formulation development and analytical testing to clinical manufacturing for early-stage therapies.

Integrated Platform for Early-Stage Clinical Supply

Kenox’s upgraded infrastructure enables small-scale fill-finish operations for small molecules, peptides, and biologics, supporting batch sizes suitable for Phase I and Phase II clinical trials. The company also offers formulation development, device optimization, and regulatory support for inhalation technologies such as nebulizers, soft-mist inhalers, dry powder inhalers, and nasal sprays. These capabilities are designed to reduce development risk and accelerate clinical readiness for emerging therapies.

Advancing Therapies Through Nasal and Inhalation Delivery

With its expanded capabilities, Kenox aims to support drug programs targeting neurological, pulmonary, and rare diseases. The company is particularly focused on therapies leveraging nose-to-brain delivery for conditions such as Alzheimer’s disease and Parkinson’s disease, as well as respiratory disorders like asthma and COPD. By integrating development and manufacturing under one roof, Kenox seeks to help biopharma partners shorten timelines from discovery to clinical trials.